INDP — Indaptus Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1857044 ·
Last close
$3.32
Market Cap
$442.36M
52W High
$5.96
52W Low
$0.92
ADV30
324,818
Next earnings
—
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,808,866 -1,794,863 11,987,956 7,553,820 615,426
Mar 2026 0 — -2,159,588 -2,541,070 2,180,856 1,497,635 932,999
Dec 2025 0 — -8,155,704 -8,112,450 9,310,168 8,507,628 6,158,575
Sep 2025 0 — -2,648,487 -2,975,117 6,840,052 5,825,639 2,234,325

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,695,567
Investing CF
—
Financing CF
$20,091,686
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.32
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-85,624,032
Inventory
—
Receivables
—
ST Investments
$4,000,000
EBIT TTM
$-14,772,645
Pretax Income TTM
$-15,423,500
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -19,833,513 -20,848,916 9,310,168 6,158,575 3,151,593 -14,823,256
Dec 2024 0 -15,365,751 -15,022,027 7,338,756 3,393,881 3,944,875 -12,323,188
Dec 2023 0 -16,378,474 -15,423,471 14,923,878 2,847,380 12,076,498 -13,405,315
Dec 2022 0 -14,910,906 -14,322,798 28,063,806 3,433,341 24,630,465 -13,078,347
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-15,423,500
OpCashFlow TTM
—
Assets (Latest)
$11,987,956
Forward EPS
$-1.39

Peers — same industry

TickerNameMarket CapLastDaily %
EOLS Evolus, Inc. $442.80M $6.69 —
ARVN ARVINAS, INC. $446.61M $6.82 —
PHAT Phathom Pharmaceuticals, Inc. $447.10M $5.50 —
EPRX EUPRAXIA PHARMACEUTICALS INC. $437.41M $6.62 —
DMAC DiaMedica Therapeutics Inc. $452.16M $8.38 —

News headlines (Yahoo Finance, 1h cache)

Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 21:05 · Yahoo
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:00 · Yahoo
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
2026-09-25 03:23 · Yahoo
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-13 11:00 · Yahoo
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
2025-12-29 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.